Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04860830 · ClinicalTrials.gov registry record · Phase 3
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 609
- Enrollment target
NCT04860830 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 609 participants.
The verdict
NCT04860830, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 609 participants
- Enrollment target
Study Summary
This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Examples include struggling to remember things, or to read a book or pay attention to a movie. Some people have difficulty calculating the right change or planning a trip so that they arrive on time. The purpose of this study is to find out whether a medicine called iclepertin improves learning and memory in people with schizophrenia. Participants are put into two groups randomly, which means by chance. One group takes iclepertin tablets and the other group takes placebo tablets. Placebo tablets look like iclepertin tablets but do not contain any medicine. Participants take a tablet once a day for 26 weeks. In addition, all participants take their normal medication for schizophrenia. During this time, doctors regularly test learning and memory of the participants by use of questionnaires, interviews, and computer tests. The results of the mental ability tests are compared between the groups. Participants are in the study for about 8 months and visit the study site about 14 times. During this time, doctors regularly check participants' health and take note of any unwanted effects.
Interventions
- DRUG Placebo
- DRUG Iclepertin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2024-11-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04860830
The ClinicalTrials.gov registry entry for NCT04860830 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04860830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04860830 about?
NCT04860830 is a clinical study titled "CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia". This study is open to adults with schizophrenia. Schizophrenia can affect the way a person thinks, their memory and their mental functioning. Examples include struggling to remember things, or to read a book or pay attention to a movie. Some people have difficulty calculating the right change or pla...
What is the current status of trial NCT04860830?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2021-08-09. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT04860830?
The interventions under investigation include: Placebo (DRUG), Iclepertin (DRUG).
Who is sponsoring clinical trial NCT04860830?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.